Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors Journal Article

  


Authors: Kondagunta, G. V.; Motzer, R. J.
Article Title: Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors
Abstract: Management options for patients who have stage II nonseminomatous germ cell cancer, completely resected at retroperitoneal lymph node dissection (RPLND), include two cycles of adjuvant cisplatin-based chemotherapy or close surveillance, with chemotherapy reserved for patients who relapse. Both options are associated with cure in an equally high percentage of patients. The choice of options is influenced by the extent of the tumor resected and patient compliance. Surveillance is a strong consideration for patients who have low-volume nodal disease at RPLND because the relapse proportion is 30% or less. In contrast, patients who have high-volume nodal involvement at RPLND have a relapse rate of 50% to 90% with surveillance alone, and adjuvant chemotherapy is the preferable option in this group.
Keywords: cisplatin; etoposide; combination chemotherapy; dissection; bleomycin; lymph-node; randomized-trial; metastatic testicular cancer; retroperitoneal lymphadenectomy; seminomatous testis tumors; actinomycin-d
Journal Title: Urologic Clinics of North America
Volume: 34
Issue: 2
ISSN: 0094-0143
Publisher: W.B. Saunders Co-Elsevier Inc.  
Date Published: 2007-05-01
Start Page: 179
End Page: 185
Language: English
ACCESSION: WOS:000246935900010
DOI: 10.1016/j.ucl.2007.02.005
PROVIDER: wos
PUBMED: 17484923
Notes: --- - Article - "Source: Wos"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gnanamba Kondagunta
    46 Kondagunta
  2. Robert Motzer
    1243 Motzer
Related MSK Work